No profile data available.
T2 Biosystems, Inc. (TTOO) is a healthcare company in the chemical laboratory testing equipment industry, based in Lexington, United States, with about 113 full-time employees.
It reported revenue of $7.19 million for fiscal year 2023, down 67.8% from fiscal year 2022, and net income of -$50.08 million. In Q3 2024 (the quarter ended September 30, 2024) revenue was $1.99 million, up 34.9% from a year before. United States was its largest region in fiscal year 2023, with 62% of revenue. Its market capitalization was $16,827 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of October 8, 2026.
T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.
T2 Biosystems reported $7.19 million in revenue for fiscal year 2023, down 67.8% from $22.31 million in fiscal year 2022. In Q3 2024 revenue was $1.99 million.
United States: 62% of revenue by region in fiscal year 2023, followed by Other International (19%).
$16,827 as of October 8, 2026.
Listed companies of a similar size in the same industry (chemical laboratory testing equipment) include Bluejay Diagnostics, Inc. (BJDX), Axim Biotechnologies, Inc. (AXIM), GlucoTrack, Inc. (GCTK), Cue Health Inc. (HLTHQ).